11/9/2026

speaker
Conference Operator
Operator

Welcome to the Medicus Pharma third quarter 2026 Financial Performance and Business Update conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad. To withdraw your question, please press star and then two. Please note this event is being recorded. I would now like to turn the conference over to Anna Djokovic, Senior Vice President of Investor Relations. Please go ahead.

speaker
Anna Djokovic
Senior Vice President, Investor Relations

Thank you. Hello and welcome. This is Anna Djokovic, Senior Vice President, Investor Relations at Medicaid Pharma. Thank you for joining our financial performance and business update call for the third quarter and nine months ended September 30th, 2026. Joining me today are Dr. Raza Bokhari, our Executive Chairman and Chief Executive Officer, Karen Bonner, our President and Chief Financial Officer, and Dr. Faisal Mehmud, our Chief Medical Officer. Before we begin, some of the matters discussed today contain forward-looking statements within the meaning of applicable securities laws, including statements about clinical development, regulatory plans, the Pfizer collaboration, potential partnerships, the proposed skinject business combination and related financing, financing requirements and NASDAQ compliance. These statements reflect management's current expectations as of today and are subject to risks and uncertainties that could cause actual results to differ materially. Please review the risks described in our most recent annual report on Form 10-K, our quarterly report on Form 10-Q and other SEC filings. Medicaid undertakes no obligation to update forward-looking statements except as required by law. All financial amounts discussed are in U.S. dollars. Our product candidates are investigational and have not been approved by the FDA or any other regulatory authority for commercial sale. With that, I would like to turn the call over to Dr. Raza Bokhari. Dr. Bokhari?

speaker
Dr. Raza Bokhari
Executive Chairman and Chief Executive Officer

Thank you, Anna. On behalf of the entire Medicus team, thank you all for joining us today. During the first nine months of 2026, Medicus took an important step in its transformation into a precision oncology-led biotechnology company, advancing a capital-efficient drug development strategy. Our agreement with Pfizer gives us worldwide rights to a clinical stage antibody drug conjugate with a differentiated target and a substantial scientific and development foundation. We believe this creates an opportunity to build long-term shareholder value by advancing a potential new treatment for patients whose cancer resists We have also announced a non-binding letter of intent for a proposed business combination involving Skinjet at a $135 million pre-money enterprise valuation with concurrent equity financing contemplated at closing of the business combination. We believe A separately listed skinjet company in which Medicus seeks to retain majority economic and voting ownership could unlock value for shareholders and support development in golden syndrome while allowing Medicus to concentrate incremental investment on precision oncology. Now I will go in some relevant details of the Pfizer agreement. On September 2nd, through our wholly-owned subsidiary, Medicus Pharma Inc., doing business as Medicus Oncology, we entered into a co-development and license agreement with Pfizer for PF-08046031, which we refer to as CD228V. Subject to the agreement's retained rights and other provisions, we hold an exclusive worldwide license to develop, manufacture, and commercialize the program. Medicus has authority over program execution, including development, manufacturing, regulatory approval, and commercialization. Faisal remains involved under the co-development framework. Faisal also provided $2 million for development activities and retains the right without an obligation to elect to fund all or part of the development beginning with the first pivotal trial. CD228V is a second generation construct originating from Cgen and subsequently advanced by Pfizer. The earlier molecule, SGN-CD228A, generated preliminary clinical observations and insights into the target, safety, and biomarkers. CD228V uses Pfizer's established Bedodin linker payload platform with changes to the linker and the amount of payload carried by each antibody. It is our understanding these refinements were designed to improve the balance between drug exposure, tolerability, and anti-tumor activity. Our decision to enter into the co-development and license agreement with Pfizer was informed by our review of the clinical data from Segen's open-label Phase 1 study of SGN-CD228A, which enrolled 88 patients with advanced solid tumors, including melanoma, and Non-Small Cell Lung Cancer. Detailed findings from that study have not yet been publicly disclosed. Our review of those data together with Pfizer's scientific rationale for reconstructing the linker payload using Vidotin gave us confidence in the therapeutic potential of CD228V. The Vidotin linker payload technology has established clinical and regulatory precedent through its use in FDA-approved ADC therapies. Our initial focus is melanoma, particularly disease that has relapsed, become refractory or resisted immunotherapy. We believe this is a compelling starting point based on CD228 biology and the available expression data. Concentrating on a defined patient population allows us to ask a focused clinical question and use the resulting evidence to guide future investment. Based on our assessment of the available clinical evidence from SGN-CD228A season study and the potential benefit of Pfizer's linker payload reconstruction, we believe CD228V has the potential to achieve an objective response rate exceeding 30% in melanoma. This would represent a clinically meaningful efficacy benchmark that could support a future FDA monotherapy registration strategy, subject to demonstration of durable responses, an acceptable safety profile, and applicable regulatory requirements. This potential remains to be demonstrated in clinical trials of CD228V. We see Medicus as part of an emerging group of approximately 30 clinical stage ADC developers across the globe. At one end of this field are established companies with approved products and extensive development capabilities. At the other end are companies with programs still in clinical research and development. Through CD228V, Medicus has a clinical state asset built on an established ADC platform. Our agreement with Pfizer also places Medicus amongst a list of handful companies advancing season-linked ADC assets through Pfizer collaborations. The rights, economics, and clinical maturity of those relationships differ. For our shareholders, we believe the opportunity lies in the combination of our worldwide rights, the clinical evidence that we already have, and the clinical evidence we intend to generate, which could support a broader development program and inform future licensing, co-development or other strategic discussions. We intend to earn that opportunity through our clinical progress while directing capital towards the milestones most likely to improve our understanding of the asset. Now I will turn to relevant progress for our Skinjet asset and proposed business combination. I'm excited to share that we announced on November 4th that Skinjet has entered into a non-binding letter of intent with an undisclosed SPAC. The proposed business combination contemplates a $135 million pre-money enterprise valuation for Skinjet with concurrent equity financing at closing to support Skinjet 005 study in Golan Syndrome and preparation and submission of a potential new drug application. Our projected estimate for this program is approximately $3 million spread over the next two years. Under the proposed terms, the SPAC would acquire 100% of Skinjet in exchange for newly issued common shares of the combined company. Our objective is for Medicus to retain majority economic and voting ownership of the combined company. We believe a separately listed company with its own public market access and dedicated financing platform could help unlock Skinjet's value while preserving Medicus shareholders' participation in its potential future growth. We will continue allocating essential resources to maintain program readiness as the proposed transaction progresses. We currently anticipate completing the proposed business combination during the first half of 2027. There can be no assurance that definitive agreements will be signed, that financing will be secured, or their transaction will close within the timeframe or at all. Now I will move to our Teverelics with relevant updates. As we advance our transformation into precision oncology led biotechnology company, we increasingly view Teverelics as offering partner ready opportunities in acute urinary retention relapse prevention, advanced prostate cancer, and women's health. Our optimized prostate cancer protocol remains subject to FDA feedback. We are maintaining program readiness while seeking partners with the capability and resources to advance these opportunities. Across the portfolio, Our priority is to concentrate incremental development investment on CD228V, pursue the proposed skinjet transaction, and preserve Teverelic's partnering readiness. Our financial results reflect the cost of establishing our portfolio of assets, including the recently completed co-development and licensing agreement with Pfizer for CD228V. I will now turn the call over to our President and Chief Financial Officer, Carolyn Bonner, for the financial review.

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API

Investor presentation